Belinostat (PXD101)

For research use only.

Catalog No.S1085 Synonyms: NSC726630, PX-105684

60 publications

Belinostat (PXD101) Chemical Structure

CAS No. 414864-00-9

Belinostat (PXD101, NSC726630, PX-105684) is a novel HDAC inhibitor with IC50 of 27 nM in a cell-free assay, with activity demonstrated in cisplatin-resistant tumors. Belinostat (PXD101) induces autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 160 In stock
USD 120 In stock
USD 370 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Belinostat (PXD101) has been cited by 60 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Belinostat (PXD101, NSC726630, PX-105684) is a novel HDAC inhibitor with IC50 of 27 nM in a cell-free assay, with activity demonstrated in cisplatin-resistant tumors. Belinostat (PXD101) induces autophagy.
Features Lead compound of Topotarget.
Targets
HDAC [1]
(Cell-free assay)
27 nM
In vitro

Belinostat inhibits the growth of tumor cells (A2780, HCT116, HT29, WIL, CALU-3, MCF7, PC3 and HS852) with IC50 from 0.2-0.66 μM. PD101 shows low activity in A2780/cp70 and 2780AD cells, which are cisplatin and doxorubicin-resistant derivatives of A2780 cells. Belinostat could induce apoptosis through PARP cleavage and acetylation of histones H3/H4. [1] Belinostat inhibits bladder cancer cell growth, especially in 5637 cells, which shows accumulation of G0-G1 phase, decrease in S phase and increase in G2-M phase. [2] The growth inhibitory activity of belinostat on cell lines is not strongly influenced by the multidrug-resistant phenotype, whereas the activity of docetaxel is clearly affected. Belinostat could enhance the growth inhibitory activity of docetaxel or carboplatin in OVCAR-3 and A2780 cells. Belinostat also shows enhanced tubulin acetylation in ovarian cancer cell lines. [3] A recent study shows that Belinostat activates protein kinase A in a TGF-β signaling-dependent mechanism and decreases survivin mRNA. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NB4 NXHweGZNS2WubDDWbYFjcWyrdImgRZN{[Xl? M4TUcVAvOi9{wrFOwG0> NXzjd|JIOjRxNEivO|IhcA>? MWfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK= Mo\XNlU5PjR5M{K=
HL-60  Mnf2R4VtdCCYaXHibYxqfHliQYPzZZk> NUH3cJFsOC5{L{NCpO69VQ>? MnLFNlQwPDhxN{KgbC=> Mn\Q[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MV6yOVg3PDd|Mh?=
NB4 Mk\ESpVv[3Srb36gRZN{[Xl? M1GzPFLDqM7:TR?= MXiyOE81QCCq MUHicI9kc3NiY3XscEBkgWOuZTDpckBUKHCqYYPl NEXSeogzPTh4NEezNi=>
HL-60  MWTGeY5kfGmxbjDBd5NigQ>? NIXIUGczyqEQvF2= MXmyOE81QCCq NWq5WolQ[myxY3vzJINmdGxiY4njcIUhcW5iUzDwbIF{\Q>? M1jYWFI2QDZ2N{Oy
NB4 Mk\HSpVv[3Srb36gRZN{[Xl? M4\Sb|AvOsLizszN Ml7iNlQwPDhxN{KgbC=> NV7s[IhJ\W6qYX7j[ZMhWkFvaX7keYNm\CCpcnHueYxw[3m2aXOg[Iln\mW{ZX70bYF1cW:w MXyyOVg3PDd|Mh?=
HL-60  NITpVZVHfW6ldHnvckBCe3OjeR?= NGLKRXMxNjMEoN88US=> M4HlZlI1NzR6L{eyJIg> NYLuc41F\W6qYX7j[ZMhWkFvaX7keYNm\CCpcnHueYxw[3m2aXOg[Iln\mW{ZX70bYF1cW:w MlnZNlU5PjR5M{K=
PANC-1 M2\iSGZ2dmO2aX;uJGF{e2G7 M4DKfVExyqEQvF2= NIr0VZMzNzRxNjDo NYnTNYJsTE2VTx?= MWXpcoR2[2W|IFHNVGsh[WO2aY\heIlwdg>? NEPrb5kzOzd2M{G5PC=>
PANC-1 NUXmbmRYS2WubDDWbYFjcWyrdImgRZN{[Xl? NXLVbI15OS9zMNMg{txO NILMPY81QCCq NUW0WVgxTE2VTx?= M3m1O4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NEPKZ|kzOzd2M{G5PC=>
PANC-1 NY[1cZpTTnWwY4Tpc44hSXO|YYm= M1jP[VExyqEQvF2= M{XKPFIwPCCq NWP6XGFQTE2VTx?= MmP3bY5kemWjc3XzJIlvfHKjY3XscJVt[XJiUl;TJIxmfmWu NHzReXgzOzd2M{G5PC=>
H1666 MoTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\BblczyqCq MojqSG1UVw>? Ml\3TWM2OD5zMDFOwG0> Mn\1NlM2OTV5NUK=
H460 M2jXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknaO|LDqGh? M2\He2ROW09? MYDJR|UxRTBwOE[g{txO MYCyN|UyPTd3Mh?=
H1299 NHO3c|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XEXVczyqCq NWDHfZI5TE2VTx?= Mk\XTWM2OD1zLkKg{txO M3WzfVI{PTF3N{Wy
H520 NGDG[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrnO|LDqGh? NXfoVJJOTE2VTx?= NGnkUWJKSzVyPUCuO|Uh|ryP Mk\5NlM2OTV5NUK=
H1975 M3i0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYe3NuKhcA>? NGna[ZNFVVOR NEn6fIlKSzVyPUCuOlgh|ryP M3vtblI{PTF3N{Wy
H1650 MkjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvBO|LDqGh? NHzQOmVFVVOR NXOzbZNoUUN3ME2wMlg5KM7:TR?= NEfpWnYzOzVzNUe1Ni=>
H820 NWXSdW81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHFUmQ4OsLiaB?= M4jGXmROW09? M4HSbWlEPTB;MD60JO69VQ>? NVjZWFRXOjN3MUW3OVI>
PC9 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrkUVE4OsLiaB?= NF2xNGFFVVOR MnfLTWM2OD1yLkK5JO69VQ>? MVWyN|UyPTd3Mh?=
HCC2279 NYD3OlJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYK3NuKhcA>? MnnqSG1UVw>? M{ntb2lEPTB;MD60JO69VQ>? MVqyN|UyPTd3Mh?=
HCC827 NUnXZpp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmyRWY4OsLiaB?= NWDsbJFjTE2VTx?= M3qyeWlEPTB;MD6yPUDPxE1? NGXlbpYzOzVzNUe1Ni=>
HCC2935 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVO3NuKhcA>? MWjEUXNQ M3nqfGlEPTB;MD65O{DPxE1? NX25fWpGOjN3MUW3OVI>
HCC4006 M2PDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3ruUFczyqCq NHSwdJlFVVOR NG\p[IhKSzVyPUCuOFYh|ryP M2HMTFI{PTF3N{Wy
H460 NWPtXI5LTnWwY4Tpc44hSXO|YYm= NYjacY84PTBywrDuUS=> NXnWSmVmOjUEoHi= MlfvSG1UVw>? NVvNeGhW\GWlcnXhd4V{KEWJRmKg[ZhxemW|c3nvci=> MkfPNlM2OTV5NUK=
H1650 NEewZ45HfW6ldHnvckBCe3OjeR?= MkX0OVAxyqCwTR?= NVTJflZFOjUEoHi= MnjmSG1UVw>? M{jm[YRm[3KnYYPld{BGT0[UIHX4dJJme3Orb36= NV7wNod[OjN3MUW3OVI>
PC9 Mn\WSpVv[3Srb36gRZN{[Xl? MYi1NFDDqG6P M1rZWlI1yqCq MWHEUXNQ MUPk[YNz\WG|ZYOgSWdHWiCneIDy[ZN{cW:w M3rVT|I{PTF3N{Wy
H460 NFizOnVHfW6ldHnvckBCe3OjeR?= NIf1dlQxNjVxMT:yJO69VQ>? NV6wVIhqPCCq NF3BbVVFVVOR M{W0PYlvcGmkaYTzJJRp\SCuZY\lcJMhd2ZiQXv0JEhxNUGtdDmgZY5lKEWJRmK= M1zwNlI{PTF3N{Wy
H1650 NI\LRWxHfW6ldHnvckBCe3OjeR?= NIL3fY4xNjVxMT:yJO69VQ>? NVvjN4xiPCCq MVrEUXNQ MoO4bY5pcWKrdIOgeIhmKGyndnXsd{Bw\iCDa4SgLJAuSWu2KTDhcoQhTUeIUh?= M2rmOFI{PTF3N{Wy
PC9 MmHBSpVv[3Srb36gRZN{[Xl? MXWwMlUwOS9{IN88US=> M4Hod|QhcA>? NIjCUVdFVVOR M{fHVolvcGmkaYTzJJRp\SCuZY\lcJMhd2ZiQXv0JEhxNUGtdDmgZY5lKEWJRmK= MnrZNlM2OTV5NUK=
AsPc1 NU\URWNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPuVYc1QCCq M1jZe2VEPTB;MD6zJO69VQ>? MnnYNlM1PzV4OUW=
Panc0327 MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjFc3U1QCCq NFn6fJBGSzVyPUCuOUDPxE1? NGDO[YgzOzR5NU[5OS=>
MiaPaCa2 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVK0PEBp NWTWd5VpTUN3ME2wMlch|ryP MVuyN|Q4PTZ7NR?=
BxPc3 NGHpdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknPOFghcA>? NVvTTYJoTUN3ME2xMlAh|ryP MUKyN|Q4PTZ7NR?=
Panc0403 MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVy0PEBp NVXnR|BoTUN3ME2xMlEh|ryP NIfNflUzOzR5NU[5OS=>
Panc1005 NFTEXYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;PXlQ5KGh? NUexc|YxTUN3ME2xMlEh|ryP NFzUOFUzOzR5NU[5OS=>
PL45 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLjOFghcA>? MorYSWM2OD1{MD64JO69VQ>? MnW0NlM1PzV4OUW=
Panc0203 MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfjT|g1QCCq M1;VSmVEPTB;MkKuNkDPxE1? NXWzZ45XOjN2N{W2PVU>
Panc0327 NHrCPYFCeG:ydH;zbZMhSXO|YYm= NGTH[GMyKM7:TR?= M4H3e|I1KGh? NYr6RpV2cW6mdXPld{BieG:ydH;zbZM> NUjqXVZVOjN2N{W2PVU>
Panc1005 NF36fZRCeG:ydH;zbZMhSXO|YYm= NI\yeXoyKM7:TR?= NUPRNGNjOjRiaB?= M3Hkbolv\HWlZYOgZZBweHSxc3nz M4PCeVI{PDd3Nkm1
Panc0403 MVvBdI9xfG:|aYOgRZN{[Xl? MmnRNUDPxE1? NX3VfZVJOjRiaB?= M13hWIlv\HWlZYOgZZBweHSxc3nz NFPGWXYzOzR5NU[5OS=>
AsPc1 NHrEWFFHfW6ldHnvckBCe3OjeR?= M3fRR|EwOTBizszN MUGyOEBp MmjXbY5lfWOnczCg[5Jwf3SqIHHydoV{fGWmIHnuJGczN01? NFjOVHQzOzR5NU[5OS=>
MiaPaCa2 NWKyVHo1TnWwY4Tpc44hSXO|YYm= NIXJU2cyNzFyIN88US=> NXLaeohvOjRiaB?= M2DENolv\HWlZYOgJIdzd3e2aDDhdpJme3SnZDDpckBIOi:P Mki4NlM1PzV4OUW=
T3M4 NFTNbmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\xWo0xNThyMDDuUS=> NHjTV3k1QCCq NVm5WG9IcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M165cVIzPjhzNkm4
AsPC-1 NWH3clhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3v6UlAuQDByIH7N MnTtOFghcA>? Mk\hbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MlLqNlI3QDF4OUi=
Panc-1  NUOzbYNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF62UXgxNThyMDDuUS=> M4TPZVQ5KGh? Ml3zbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NHf5bJQzOjZ6MU[5PC=>
T3M4 MVPBdI9xfG:|aYOgRZN{[Xl? NHjObZcyODBxNUCwM|ExODBibl2= MmnHOFghcA>? NGq3Z4hqdmS3Y3XzJIRwe2ViZHXw[Y5l\W62IHHwc5B1d3Orcx?= MWeyNlY5OTZ7OB?=
AsPC-1 NVz3Rmd7SXCxcITvd4l{KEG|c3H5 M{f0R|ExOC93MECvNVAxOCCwTR?= NH7Ec3E1QCCq MmX6bY5lfWOnczDkc5NmKGSncHXu[IVvfCCjcH;weI9{cXN? M2n5NlIzPjhzNkm4
Panc-1  MX;BdI9xfG:|aYOgRZN{[Xl? NFjUd|UyODBxNUCwM|ExODBibl2= MoH0OFghcA>? NXnyfYU{cW6mdXPld{Bld3OnIHTldIVv\GWwdDDhdI9xfG:|aYO= NGf0VY4zOjZ6MU[5PC=>
HBL-2 NXezPGNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7Yd2MzPCCq MYPJR|UxRTBwNDFOwG0> NILS[ZczODB4OEC4NC=>
Jeko-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCyOEBp M3rhZWlEPTB;MD6yJO69VQ>? NX3sXpRwOjByNkiwPFA>
Granta-519 M3H1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYiyOEBp NFTRfFJKSzVyPUW2MlMh|ryP MoLLNlAxPjhyOEC=
HCT116 NIixfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHsOFghcA>? NFP5NnFGSzVyPUCuNlgh|ryP NYW2[WtXOTdzMkS1PVQ>
HCT116 M1GxWWZ2dmO2aX;uJGF{e2G7 MYiwMlnDqM7:TdMg MXuyOEBp NHXoTGdld3ewLYLl[5Vt[XS|IGTTJJBzd3SnaX6gcIV3\Wy|IHHmeIVzKDcEoHigbY5kfWKjdHnvci=> MVmxO|EzPDV7NB?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PARP / p-ERK / p-p38 / p38 / p-BRAF / p-MEK / MEK ; 

PubMed: 28397399     


Cell lysates were harvested from lung SCC cells after treatment with increasing doses of belinostat (0.1, 0.2, 0.3, 1, 3 μm). Immunoblotting was performed to evaluate the changes in phosphorylated protein levels of the targets identified in 1D (ERK1/2, p38, B‐Raf, MEK1/2) as well as PARP. β‐Actin shown as loading control. 

SOS1 / SOS2; 

PubMed: 28397399     


(A) Cell lysates were harvested from lung SCC cells after treatment with increasing doses of belinostat (PXD101) (0.1, 0.2, 0.3, 1, 3 μm) to evaluate the changes in SOS1 and SOS2. 

p21 / p27 ; 

PubMed: 23982416     


(A and B) The cell lines shown were treated with PXD101 for 0, 2, 4, 8, 24, 48, and 72 h. Whole cell extracts were generated and subjected to western blotting with antibodies against p21, p27, hsp90, α-tubulin, or GAPDH. PXD101-resistant cell lines are shown in (A, left) while PXD101-sensitive cell lines are shown in (B, right). 

Acetyl Histone H3 / Acetyl Histone H4 / Acetyl tubulin; 

PubMed: 24155971     


PXD101 induced acetylation of histone H3 and histone H4 in a dose-dependent manner. PXD101 also increased acetylation of tubulin in BHP7-13, WRO82-1 and 8505C.

p-H2AX(Ser139) / KU70 / KU80 / RAD51 / RAD52 / ERCC1 ; 

PubMed: 24155971     


increasing doses of PXD101 enhanced degradation of KU70, KU80 and RAD51, and enhanced expression of p-H2AX (Ser139), RAD52 and ERCC1 in BHP7-13, WRO82-1 and 8505C.

28397399 23982416 24155971
Growth inhibition assay
IC50; 

PubMed: 28397399     


Lung SCC cell lines and normal lung fibroblast cell lines were treated with belinostat (PXD101) for 72 h, and cell viability was determined with CellTiter assay. Data are represented as mean IC50 ± SD (n = 3).

Cell viability; 

PubMed: 24155971     


Dose-response curves were obtained on day 4 from cells treated with a series of six 1:1 dilutions of PXD101. 

28397399 24155971
In vivo Belinostat indicates significant tumor growth delay in A2780 and A2780/cp70 xenograft at a dose of 10mg/kg with no effects on the body weight. [1] Belinostat also induces p21WAF1, HDAC core and cell communication genes in mouse bladder tumors. [2] Belinostat monotherapy induces dose-proportional antitumor effects with TGI of 47% at a dose of 100mg/kg in A2780 xenograft. The combination of Belinostat (100 mg/kg) with carboplatin (40 mg/kg) could delay tumor growth from 18.6 days to 22.5 days. [3] Combining with bortezomib, Belinostat results in great tumor inhibition and gastrointestinal toxicity in mice with bortezomib-resistant UMSCC-11A xenograft. [5]

Protocol

Kinase Assay:[1]
- Collapse

Histone Deacetylase Activity:

Subconfluent cultures are harvested and washed twice in ice cold PBS and pelleted by centrifugation at 200 × g for 5 min. The cell pellet is resuspended in two volumes of lysis buffer [60 mM Tris buffer (pH 7.4) containing 30% glycerol and 450 mM NaCl] and lysed by three freeze (dry ice) thaw (30 °C water bath) cycles. Cell debris is removed by centrifugation at 1.2 × 104 g for 5 min, and the supernatant is stored at −80 °C. Histone H4 peptide (sequence SGRGKGGKGLGKGGAKRHRK corresponding to the 20 NH2-terminal residues) is acetylated by a recombinant protein containing the hypoxanthine-aminopterin-thymidine domain of p300, using [3H]acetyl CoA as a source of acetate. H4 peptide (100 μg) is mixed with hypoxanthine-aminopterin-thymidine buffer (50 mM Tris HCl pH 8.0, 5% glycerol, 50 mM KCl, and 0.1 mM EDTA), 1 mM DTT, 1 mM 4-(2-aminoethyl) benzenesulfonylfluoride, 1 × complete protease inhibitors, 50 μL of purified p300, and 1.85 m [3H]acetyl CoA (4.50Ci/mmol) in a final volume of 300 μL and incubated at 30 °C for 45 min. The p300 protein is removed by incubation with 20 μL of 50% Ni-agaroase beads for 1 hour at 4 °C and centrifugation. The supernatant is applied to a 2 mL Sephadex G15 column, and the flow through is collected. One milliliter of distilled H2O is gently applied, and three drop fractions are collected; this is repeated until 4–5 mL of distilled H2O has been added, and ∼40 fractions are collected. Three microliters of each fraction are diluted in 2 mL of scintillation fluid and counted in a scintillation counter to identify the fractions containing the labeled peptide. These fractions are pooled, and 1 μL of the combined sample is measured to assess the radioactivity in every peptide batch (3-7×103 cpm/μL). For activity assays, the reaction is carried out in a total volume of 150 μL of buffer [60 mM Tris (pH 7.4) containing 30% glycerol] containing 2 μL of cell extract and, where used, 2 μL of belinostat. The reaction is started by the addition of 2 μL of [3H] labeled substrate (acetylated histone H4 peptide corresponding to the 20 NH2-terminal residues). Samples are incubated at 37 °C for 45 min, and the reaction stopped by the addition of HCl and acetic acid (0.72 and 0.12 M final concentrations, respectively). Released [3H]acetate is extracted into 750 μL of ethyl acetate, and samples are centrifuged at 1.2× 104 g for 5 min. The upper phase (600 μL) is transferred to 3 mL of scintillation fluid and counted.
Cell Research:[1]
- Collapse
  • Cell lines: A2780, A2780/cp70, 2780AD, HCT116, HT29, WIL, CALU-3, MCF7, PC3 and HS852
  • Concentrations: 0.016 - 10 μM
  • Incubation Time: 24 hours
  • Method: Tumor cell lines are seeded in 5 mL of medium at a density of 8 × 104 cells/25 cm2 flask and incubated for 48 hours. Cells are exposed to Belinostat (0.016 to 10 μM) for 24 hours. The medium is removed, and 1 mL of trypsin/EDTA is added to each flask. Once the cells have detached, 1 mL of medium is added, the cells are resuspended, and those from the control untreated flask are counted. Cells are diluted and plated into 6-cm Petri dishes (three per flask) at a density of 0.5-2× 103 cells/dish depending on the cell line. Cells from the drug-treated flasks are diluted and plated as for the control flasks. Dishes are incubated for 10–15 days at 37 °C. Cells are washed with PBS, fixed in methanol, and stained with crystal violet, and colonies that contained ≥50 cells counted. Sensitivity is expressed as the IC50 defined as the concentration of belinostat required to reduce the number of colonies to 50% of that of the control untreated cells.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: A2780, A2780/cp70 and HCT116 cells are injected s.c. into the right flank of CD1 nu/nu mice.
  • Dosages: ≤40 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 64 mg/mL (201.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 318.35
Formula

C15H14N2O4S

CAS No. 414864-00-9
Storage powder
in solvent
Synonyms NSC726630, PX-105684
Smiles C1=CC=C(C=C1)NS(=O)(=O)C2=CC=CC(=C2)C=CC(=O)NO

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04315233 Not yet recruiting Drug: Ribociclib|Drug: Belinostat Metastatic Breast Cancer|Recurrent Ovarian Carcinoma University of Utah|Novartis|Acrotech Biopharma August 2020 Phase 1
NCT03772925 Recruiting Drug: Belinostat|Drug: Pevonedistat Recurrent Acute Myeloid Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Myelodysplastic Syndrome National Cancer Institute (NCI) February 28 2019 Phase 1
NCT02680795 Recruiting Drug: Belinostat IV Solid Tumors|Hematological Malignancies Acrotech Biopharma LLC|Axis Clinicals Limited March 2016 Phase 1
NCT02679131 Terminated Drug: Belinostat Relapsed/Refractory Solid Tumors/Hematological Malignancies Acrotech Biopharma LLC|Axis Clinicals Limited March 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you please give some suggestions for the use of Belinostat in vivo (i.p. injection)?

  • Answer:

    For I.P. injection, S1085 Belinostat (PXD101) can be dissolved in 2% DMSO+30% PEG 300+ddH2O at 10 mg/ml clearly. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG, after they mixed well, then dilute with water. Hope this information is useful to you.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Belinostat (PXD101) | Belinostat (PXD101) supplier | purchase Belinostat (PXD101) | Belinostat (PXD101) cost | Belinostat (PXD101) manufacturer | order Belinostat (PXD101) | Belinostat (PXD101) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID